Wall Street already knew argenx SE (ARGX) for one drug and one fight.
Monday morning, the market priced a second chapter.
argenx said its under-the-skin shot, VYVGART Hytrulo, hit the main goal in a late-stage study of autoimmune myositis. That is a rare muscle-attacking disease where patients lose strength, lean on long-term steroids, and, in the harshest subtype, have almost nothing FDA-approved waiting for them.
The stock ripped. Shares closed near $988, up roughly 16% on the day, after trading as high as a fresh high. Several market desks called it the best single session in company history. That is not a quiet "in line" beat. That is a franchise-expansion day.
The Trial That Changed the Story
The study is called ALKIVIA. It tested efgartigimod, the same active idea behind blockbuster VYVGART, as a weekly under-the-skin injection in adults with two myositis subtypes: immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM).
In the combined group, patients on the drug improved 15.4 points more than placebo on the Total Improvement Score at week 52. The treated arm averaged about 48. The placebo arm averaged about 33. The p-value was 0.0011. In plain terms, the difference was large enough that chance is a weak explanation.
Benefits showed up early, around week 4, and held through a full year even as the protocol forced steroid tapering. That matters. Steroids help, then they punish. A drug that works while doctors try to peel steroids back is the kind of result doctors actually use.
The IMNM cut is the sharp one. That subtype is aggressive. Muscle cells break down. Approved targeted options are basically empty. ALKIVIA met the primary endpoint in IMNM on its own (p=0.0048), with roughly a 15-point edge over placebo. argenx flagged that as the first Phase 3 win of its kind in IMNM.
DM improved by a similar magnitude, about 14.5 points, but the smaller group did not clear the strict statistical bar (p=0.1093). Bulls will still call the direction supportive. Skeptics will say the label path may lean hardest on IMNM first. Both can be true.
Why the Stock Screamed
argenx did not invent a brand-new molecule on Monday. It showed the one Wall Street already trusts can reach a new patient pile.
VYVGART built the company on generalized myasthenia gravis. The commercial story has been simple: a real drug, expanding labels, under-the-skin convenience, and a biotech that keeps adding autoimmune doors. Myositis is the next door. IBD-style coverage called out the multi-billion-dollar opportunity if the franchise stretches into a disease class with limited targeted therapy.
That is the non-obvious read cable hits will miss if they only say "biotech up on trial." The question was never "does argenx have a drug?" The question was "how many diseases will pay for the same mechanism?" Monday answered with a hard clinical print, not a press-tour tease.
Traders did the rest. A 16% gap on a name already near highs is the market saying the expansion case just got more real, faster than the Street's base case.
The Catch (Because There Always Is One)
Phase 3 wins are not approvals. Filing, FDA review, labeling language, and payer fights still sit between Monday's cheer and real revenue.
The DM subgroup miss on pure statistics gives bears a footnote. Competitors in FcRn and broader immunology will not freeze. And a stock that just printed a historic up day can give some of it back on any whisper about safety, manufacturing, or how narrow the first myositis label looks.
There is also the valuation tax. When a company becomes "the Vyvgart platform," every new indication is already partly in the price. ALKIVIA has to turn into a commercial chapter, not just a one-day chart spike.
Bottom Line
Monday was not about argenx learning to run a trial. It was about Wall Street repricing how wide the VYVGART franchise can get.
A first-of-its-kind IMNM Phase 3 win, a clean combined primary endpoint, early and durable strength gains while steroids come down, and a roughly 16% best-day rip near $988. That is a story stock, not a spreadsheet stock.
What to watch next is boring and decisive: the regulatory path for IMNM, how loud argenx talks about DM, and whether the commercial machine can turn a muscle disease win into the same kind of franchise money myasthenia already pays. The trial did its job. Now the company has to finish the business.
Comments
Log in or sign up to join the conversation.